Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Mehr anzeigen
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate...
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal...
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.35 | 2.91909924937 | 11.99 | 12.57 | 11.19 | 101720 | 11.93297886 | CS |
| 4 | 0.35 | 2.91909924937 | 11.99 | 14.19 | 11.19 | 144011 | 12.78599062 | CS |
| 12 | 0.24 | 1.98347107438 | 12.1 | 15.25 | 11.19 | 174016 | 13.31232878 | CS |
| 26 | 0.59 | 5.02127659574 | 11.75 | 15.25 | 8.58 | 198077 | 12.56491444 | CS |
| 52 | 4.46 | 56.5989847716 | 7.88 | 16.905 | 7.29 | 175363 | 12.63800781 | CS |
| 156 | -8.76 | -41.5165876777 | 21.1 | 21.98 | 5.85 | 185588 | 12.89322856 | CS |
| 260 | -8.76 | -41.5165876777 | 21.1 | 21.98 | 5.85 | 185588 | 12.89322856 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
